Tuesday 5 November 2024

The Pharmaletter

One To Watch

Vaxcyte

A clinical-stage innovation company engineering high-fidelity vaccines.

Company Overview

Want to Update your Company's Profile?


Latest Vaxcyte News

Top-line results further validate potential of Vaxcyte’s VAX-31
3 September 2024
Vaxcyte's pneumococcal vaccine data drives share price jump
18 April 2023
Vaxcyte soars on positive data from Phase I/II study of VAX-24
24 October 2022
More Vaxcyte news >


Today's issue

AstraZeneca sees progress in obesity drug trials, highlights new oral option
Pharmaceutical
AstraZeneca sees progress in obesity drug trials, highlights new oral option
5 November 2024
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze